COVID-19 Research Guide: Therapeutics

Updated multiple times since original publication in September 2020.

PubMed search for English-language practice guidelines on COVID-19.

Displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority.

Identifies and and tracks all treatments reported to be used for COVID-19 in an open-source data repository. Produced by the Castleman Disease Collaborative Network.

BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create a granular, interactive view of the Covid-19 pipeline.

Table lists pertinent evidence on the clinical effectiveness and safety of some drugs and other therapies being considered for COVID-19. Most authorities recommend use of these drugs only in the setting of a clinical trial or when access via clinical trial is not available. Inclusion in this table is not a recommendation for use for treatment of COVID-19.

Regularly updated list of drugs and treatments for COVID-19

Database that identifies correlations between drug-like substances with potential antiviral activity and COVID-19 protein targets.

ClinicalTrials.gov search for clinical trials on COVID-19 including upcoming, recruiting, and completed trials.

NCATS is generating a collection of datasets by screening a panel of SARS-CoV-2-related assays against all approved drugs. Datasets, as well as the assay protocols used to generate them, are made immediately available to the scientific community on this site as the screens are completed.

The Data Portal brings together COVID-19 datasets and tools to facilitate data sharing and analysis, and to accelerate coronavirus research. The COVID-19 Data Portal enables researchers to upload, access and analyze COVID-19 related reference data and specialist datasets.

U.S.-based centralized national data resource that the research community can use to study COVID-19 and identify potential treatments; the N3C will enable the rapid collection and analysis of clinical, laboratory and diagnostic data from hospitals and health care plans.

Promotes the rapid sharing of data from all influenza viruses and the coronavirus causing COVID-19, including genetic sequence and related clinical and epidemiological data associated with human viruses, and geographical as well as species-specific data associated with avian and other animal viruses, to help researchers understand how viruses evolve and spread during epidemics and pandemics.